Dipyridamole and Adenosine Interaction
Drug interaction information between Dipyridamole and Adenosine.
Dipyridamole and Adenosine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Dipyridamole and Adenosine. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Dipyridamole causes adenosine levels to build up in the blood, which can make the effects on your heart and blood vessels stronger.
FDA Label Information
Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist.
Dipyridamole Also Interacts With
- Heparin moderate
- Warfarin moderate
- Enoxaparin minor
- Nicardipine minor
Frequently Asked Questions
What SPL severity band is on file for Dipyridamole + Adenosine?
Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Dipyridamole has 5 labeled pairs on file vs Adenosine's 2. In the minor band specifically: Dipyridamole has 3 (also Enoxaparin, Nicardipine); Adenosine has 2 (also Theophylline).
What mechanism field is on file for Dipyridamole and Adenosine?
Dipyridamole causes adenosine levels to build up in the blood, which can make the effects on your heart and blood vessels stronger.
Dipyridamole's labeled portfolio outnumbers Adenosine
SPL source-record counts only. This page's band is minor · classes on file: Dipyridamole (Antiplatelet / Vasodilator); Adenosine (Endogenous Nucleoside (Antiarrhythmic)).
0 major · 2 moderate · 3 minor · 5 total
- Other minor peers for Dipyridamole
- Enoxaparin
- Nicardipine
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.